<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font21 { font-size : 21; } .font28 { font-size : 28; } .font29 { font-size : 29; } .font31 { font-size : 31; }</style>
 <body>
  <p>
   <span class="font31">DDIs </span>
   <span class="font29">(.) </span>
   <span class="font29">HCV </span>
   <span class="font28">patients </span>
   <span class="font21">outpatient </span>
   <span class="font20">:–. </span>
   <span class="font20">potential </span>
   <span class="font19">treatment </span>
   <span class="font18">medications </span>
   <span class="font18">hepatitis </span>
   <span class="font17">DAA </span>
   <span class="font16">antiviral </span>
   <span class="font16">interactions </span>
   <span class="font16">medication </span>
   <span class="font16">{border-style </span>
   <span class="font16">therapy </span>
   <span class="font15">.%, </span>
   <span class="font15">px;} </span>
   <span class="font15">regimens </span>
   <span class="font15">#ffffff;} </span>
   <span class="font15">chronic </span>
   <span class="font15">significant </span>
   <span class="font14">frequency </span>
   <span class="font14">genotype </span>
   <span class="font14">risk </span>
   <span class="font14">used </span>
   <span class="font14">Engl </span>
   <span class="font14">Med; </span>
   <span class="font14">DDI </span>
   <span class="font14">[]. </span>
   <span class="font14">al.collab: </span>
   <span class="font14">concomitant </span>
   <span class="font14">drugs </span>
   <span class="font14">fees </span>
   <span class="font13">infection. </span>
   <span class="font13">liver </span>
   <span class="font13">personal </span>
   <span class="font13">received </span>
   <span class="font13">regular </span>
   <span class="font13">(category </span>
   <span class="font13">DAAs </span>
   <span class="font13">cirrhosis </span>
   <span class="font13">clinical </span>
   <span class="font13">data </span>
   <span class="font13">infection </span>
   <span class="font13">mechanisms </span>
   <span class="font13">virus </span>
   <span class="font13">years </span>
   <span class="font13">CYP </span>
   <span class="font13">different </span>
   <span class="font13">interaction </span>
   <span class="font13">patient </span>
   <span class="font13">treated </span>
   <span class="font12">(–) </span>
   <span class="font12">However, </span>
   <span class="font12">Table </span>
   <span class="font12">modern </span>
   <span class="font12">relevant </span>
   <span class="font12">showed </span>
   <span class="font12">significantly </span>
   <span class="font12">work </span>
   <span class="font12">advanced </span>
   <span class="font12">drug–drug </span>
   <span class="font12">higher </span>
   <span class="font12">lower </span>
   <span class="font12">px; </span>
   <span class="font12">time </span>
   <span class="font12">{font-family </span>
   <span class="font12">(.%) </span>
   <span class="font12">(A: </span>
   <span class="font12">(Figure </span>
   <span class="font12">.%; </span>
   <span class="font12">Gilead, </span>
   <span class="font12">Overall, </span>
   <span class="font12">P = ., </span>
   <span class="font12">analysis </span>
   <span class="font12">font-size </span>
   <span class="font12">frequently </span>
   <span class="font12">period </span>
   <span class="font12">real-world </span>
   <span class="font12">regimens, </span>
   <span class="font12">ribavirin </span>
   <span class="font12">sofosbuvir </span>
   <span class="font12">using </span>
   <span class="font11">(.%), </span>
   <span class="font11">(Supplementary </span>
   <span class="font11">(ie, </span>
   <span class="font11">AbbVie, </span>
   <span class="font11">A–C </span>
   <span class="font11">Hannover </span>
   <span class="font11">Interactions </span>
   <span class="font11">Medical </span>
   <span class="font11">[–]. </span>
   <span class="font11">age </span>
   <span class="font11">analyzed </span>
   <span class="font11">available </span>
   <span class="font11">combination </span>
   <span class="font11">disease </span>
   <span class="font11">double; </span>
   <span class="font11">efficacy </span>
   <span class="font11">increased </span>
   <span class="font11">individual </span>
   <span class="font11">mainly </span>
   <span class="font11">new </span>
   <span class="font11">periods </span>
   <span class="font11">proportion </span>
   <span class="font11">regimens. </span>
   <span class="font11">(.%; </span>
   <span class="font11">(MSD), </span>
   <span class="font11">(n = ), </span>
   <span class="font11">A–B </span>
   <span class="font11">B–C </span>
   <span class="font11">DDIs, </span>
   <span class="font11">DDIs. </span>
   <span class="font11">Drug–Drug </span>
   <span class="font11">Figure </span>
   <span class="font11">Furthermore, </span>
   <span class="font11">Infect </span>
   <span class="font11">InvestigatorsLedipasvir </span>
   <span class="font11">Merck </span>
   <span class="font11">No. </span>
   <span class="font11">Potential </span>
   <span class="font11">Squibb, </span>
   <span class="font11">Supplementary </span>
   <span class="font11">VOX: </span>
   <span class="font11">approved </span>
   <span class="font11">assessed </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">case </span>
   <span class="font11">changed </span>
   <span class="font11">changes </span>
   <span class="font11">cirrhosis. </span>
   <span class="font11">cohort </span>
   <span class="font11">compared </span>
   <span class="font11">direct-acting </span>
   <span class="font11">drug-drug </span>
   <span class="font11">important </span>
   <span class="font11">kidney </span>
   <span class="font11">like </span>
   <span class="font11">mean </span>
   <span class="font11">medications, </span>
   <span class="font11">older </span>
   <span class="font11">patients. </span>
   <span class="font11">polypharmacy </span>
   <span class="font11">previously </span>
   <span class="font11">regimen </span>
   <span class="font11">relevance </span>
   <span class="font11">safety </span>
   <span class="font11">solid; </span>
   <span class="font11">support </span>
   <span class="font11">www.hep-druginteractions.org </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font11">(%) </span>
   <span class="font11">(HCV) </span>
   <span class="font11">.%), </span>
   <span class="font11">Bristol </span>
   <span class="font11">Cohort </span>
   <span class="font11">Forum </span>
   <span class="font11">Gastroenterology; </span>
   <span class="font11">GordonSC, </span>
   <span class="font11">Hepatol; </span>
   <span class="font11">IFN-free </span>
   <span class="font11">January </span>
   <span class="font11">July </span>
   <span class="font11">Liver </span>
   <span class="font11">Merck, </span>
   <span class="font11">Myers </span>
   <span class="font11">P-gp </span>
   <span class="font11">P = .) </span>
   <span class="font11">Study </span>
   <span class="font11">[.% </span>
   <span class="font11">antivirals </span>
   <span class="font11">approval </span>
   <span class="font11">based </span>
   <span class="font11">baseline. </span>
   <span class="font11">bold </span>
   <span class="font11">changing </span>
   <span class="font11">characteristics </span>
   <span class="font11">considered </span>
   <span class="font11">contraindicated </span>
   <span class="font11">contraindications </span>
   <span class="font11">courier; </span>
   <span class="font11">drug </span>
   <span class="font11">drugs, </span>
   <span class="font11">elderly </span>
   <span class="font11">em; </span>
   <span class="font11">epidemiology </span>
   <span class="font11">era </span>
   <span class="font11">fixed-dose </span>
   <span class="font11">highly </span>
   <span class="font11">inhibitor </span>
   <span class="font11">involved </span>
   <span class="font11">medication. </span>
   <span class="font11">options </span>
   <span class="font11">pathways </span>
   <span class="font11">patients, </span>
   <span class="font11">pegylated </span>
   <span class="font11">population </span>
   <span class="font11">provided </span>
   <span class="font11">pt;} </span>
   <span class="font11">receiving </span>
   <span class="font11">respectively. </span>
   <span class="font11">therapy, </span>
   <span class="font11">transplant </span>
   <span class="font11">various </span>
   <span class="font11">velpatasvir </span>
   <span class="font11">weak </span>
   <span class="font11">widely </span>
   <span class="font11">years. </span>
   <span class="font11">years: </span>
  </p>
 </body>
</html>
